Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303307 | 0.79 | LPL (0.48) | SMYD3CHRNB2CHRNA4MAPTHTT | |
| SCHEMBL8931090 | 0.77 | HCAR2 (0.36) | — | |
| SCHEMBL240843 | 0.77 | SMYD3 (0.39) | SMYD3CHRNB2CHRNA4MAPTHTT | |
| SCHEMBL1942394 | 0.72 | CYP11B1 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL1942335 | 0.72 | CYP11B1 (0.33) | — | |
| SCHEMBL20312299 | 0.70 | CYP19A1 (0.31) | — | |
| SCHEMBL1942145 | 0.69 | ATM (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL4783955 | 0.69 | — | — | |
| SCHEMBL30768308 | 0.69 | — | — | |
| SCHEMBL845159 | 0.67 | MAPT (0.37) | SMYD3CHRNB2CHRNA4MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088160-A2 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | SMYD3 4495/4885CHRNB2 3446/4885CHRNA4 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.